The DOI matches its Crossref record; 198 of the 206 references it cites were found in a registry or an index.
Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
Open accessAbstract
Colorectal cancer (CRC) is a predominant malignancy worldwide, being the fourth most common cause of mortality and morbidity. The CRC incidence in adolescents, young adults, and adult populations is increasing every year. In the pathogenesis of CRC, various factors are involved including diet, sedentary life, smoking, excessive alcohol consumption, obesity, gut microbiota, diabetes, and genetic mutations. The CRC tumor microenvironment (TME) involves the complex cooperation between tumoral cells with stroma, immune, and endothelial cells. Cytokines and several growth factors (GFs) will sustain CRC cell proliferation, survival, motility, and invasion. Epidermal growth factor receptor (EGFR), Insulin-like growth factor -1 receptor (IGF-1R), and Vascular Endothelial Growth Factor -A (VEGF-A) are overexpressed in various human cancers including CRC. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) and all the three major subfamilies of the mitogen-activated protein kinase (MAPK) signaling pathways may be activated by GFs and will further play key roles in CRC development. The main aim of this review is to present the CRC incidence, risk factors, pathogenesis, and the impact of GFs during its development. Moreover, the article describes the relationship between EGF, IGF, VEGF, GFs inhibitors, PI3K/AKT/mTOR-MAPK signaling pathways, and CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Increased levels of cytokines and growth factors in the TME can activate cell proliferation and survival signaling pathways in CRC cells (e.g., MAPK and PI3K/AKT) [84].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Lin, X., Wang, S., Sun, M., Zhang, C., Wei, C., Yang, C., Dou, R., Liu, Q., & Xiong, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0708-7 · Cited by 207
RetractedZhang, D., Qiu, X., Li, J., Zheng, S., Li, L., & Zhao, H. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1556064 · Cited by 72
RetractedBrenner, H., Kloor, M., & Pox, C. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61649-9 · Cited by 2,762
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Colorectal cancer statistics, 2014
Siegel, R., DeSantis, C., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21220 · Cited by 2,562
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
Kuipers, E. J., Grady, W. M., Lieberman, D., Seufferlein, T., Sung, J. J., Boelens, P. G., van de Velde, C. J. H., & Watanabe, T. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.65 · Cited by 1,563
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Aggarwal, V., Tuli, H., Varol, A., Thakral, F., Yerer, M., Sak, K., Varol, M., Jain, A., Khan, M., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom9110735 · Cited by 1,221
The MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185
Microsatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063
Research works printed but not linked: 1
- Haraldsdottir, 2014, Colorectal cancer—Review, Laeknabladid, 100, 75
Cited by
Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
Halder, S., Basu, S., Lall, S. P., Ganti, A. K., Batra, S. K., & Seshacharyulu, P. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2218613 · Cited by 133
“AKT/mTOR signaling that supports tumor cell survival, growth, and invasion [8].”
BackgroundCasado, M. E., Collado‐Perez, R., Frago, L. M., & Barrios, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021422 · Cited by 134
“Abnormal activation of this molecule due to changes in the levels of specific interleukins and growth factors is associated with the appearance of cancer [50].”
BackgroundThe Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway
Zoi, V., Kyritsis, A. P., Galani, V., Lazari, D. M., Sioka, C., Voulgaris, S., & Alexiou, G. Α. (2024) · Cancers · doi:10.3390/cancers16081554 · Cited by 119
“…inactivation of the tumor suppressor gene PTEN, and the overexpression of growth factors—such as vascular endothelial growth factor-A (VEGF-A), platelet-derived growth factor (PDGF), or epidermal growth factor (EGF)—are primarily responsible for the dysregulation of the PI3K/Akt pathway [8,9].”
BackgroundZhou, Y., Zhang, W., Wang, B., Wang, P., Li, D., Cao, T., Zhang, D., Han, H., Bai, M., Wang, X., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008054 · Cited by 107
“As a clinically applicable drug, decitabine shows great potential for promoting pyroptosis in tumors with low endogenous GSDME expression on IR700DX- 6T-PDT treatment.”
BackgroundFerraguti, G., Terracina, S. A., Petrella, C., Greco, A., Minni, A., Lucarelli, M., Agostinelli, E., Ralli, M., VINCENTIIS, M. D., Raponi, G., et al. (2022) · Antioxidants · doi:10.3390/antiox11010145 · Cited by 106
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Increased levels of cytokines and growth factors in the TME can activate cell proliferation and survival signaling pathways in CRC cells (e.g., MAPK and PI3K/AKT) [84].”
Zhang, H., Zhao, B., Wei, H., Zeng, H., Sheng, D., & Zhang, Y. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114915 · Cited by 83
Inflammatory bowel disease, colitis, and cancer: unmasking the chronic inflammation link
Khaze, V., Noorolyai, S., Youshanlui, M. A., Hossein, S., Nasiri, H., Mansoori, B., Holmskov, U., & Baradaran, B. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04748-y · Cited by 76
Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent
Zhou, C., Huang, Y., Nie, S., Zhou, S., Gao, X., & Chen, G. (2023) · European journal of medical research · doi:10.1186/s40001-023-01271-8 · Cited by 75
“Consequently, this signaling pathway regulates various cellular processes, including proliferation, apoptosis, differentiation, autophagy, and migration of cancer cells [90–94].”
BackgroundPang, B., & Wu, H. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02623-5 · Cited by 79
“Inhibition of key enzymes in the EMP pathway in CRC Elevated expression of critical EMP pathway enzymes drives therapeutic resistance in CRC, particularly to radiotherapy and chemotherapy [46].”
The effects of metabolism on the immune microenvironment in colorectal cancer
Chen, X., Ma, Z., Yi, Z., Wu, E., Shang, Z., Tuo, B., Li, T., & Liu, X. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01865-z · Cited by 71
“…(TCA) cycle, a process supported by acyl-coenzyme A (CoA) synthase, ultimately leading to enhanced levels of CD8 + tumor-in fi ltrating lymphocyte proliferation, activation and lifespan and an inhibitory effect on CRC. [17, 18] Interestingly, such a phenomenon also occurs in the absence of tumors.”
BackgroundRecent advances in targeted drug delivery systems for resistant colorectal cancer
Sharifi-Azad, M., Fathi, M., Cho, W. C., Barzegari, A., Dadashi, H., Dadashpour, M., & Jahanban-Esfahlan, R. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02605-y · Cited by 65
“Inhibitors of this pathway are therapeutic targets for CRC, however in resistant forms, mutational and epigenetic analysis could offer better portrait of CRC outcome (see for review [66]).”
BackgroundYan, C., Wang, X., Wang, Q., Li, H., Song, H., Zhou, J., Peng, Z., Yin, W., Fan, X., Yang, K. Y., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304207 · Cited by 75
Liu, X., Zhang, Y., Sun, X., Zhang, W., Xu, S., & Xu, S. (2022) · Toxicology · doi:10.1016/j.tox.2022.153226 · Cited by 64
Ameer, S. F., Mohamed, M. Y., Elzubair, Q. A., Sharif, E. A. M., & Ibrahim, W. N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1438040 · Cited by 63
Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer
Hou, X., Zheng, Z., Wei, J., & Zhao, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1030745 · Cited by 66
“These growth factors can support cancer cell proliferation, survival, motility, and invasion, by triggering the activation of MAPK, Wnt/b-catenin or PI3K/AKT/ mTOR signaling pathway, thus facilitate CRC progression (38).”
BackgroundZhong, J., Ding, S., Zhang, X., Di, W., Wang, X., Zhang, H., Chen, Y., Zhang, Y., & Hu, Y. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2802037 · Cited by 67
Kang, Z., Jiang, S., Han, J., Gao, Y., Xie, Y., Chen, J., Liu, Q., Yu, J. Q., Zhao, X., Hong, J., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166941 · Cited by 57
Najafiyan, B., Hosseini, Z. B., Esmaelian, S., Firuzpour, F., Anaraki, S. R., Kalantari, L., Hheidari, A., Mesgari, H., & Nabi‐Afjadi, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116207 · Cited by 61
Obesity-Associated Colorectal Cancer
Gonzalez-Gutierrez, L., Motiño, O., Barriuso, D., de la Puente-Aldea, J., Alvarez-Frutos, L., Kroemer, G., Palacios, R., & Senovilla, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168836 · Cited by 60
“In addition to MAPK, the PI3K/AKT/mammalian target of rapamycin (MTOR) signaling pathway may be activated and involved in CRC development [133].”
BackgroundGharib, E., & Robichaud, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179463 · Cited by 64
Molecular Hydrogen Therapy: Mechanisms, Delivery Methods, Preventive, and Therapeutic Application
Jin, J., Yue, L., Du, M., Geng, F., Gao, X., Zhou, Y., Lu, Q., & Pan, X. (2025) · MedComm · doi:10.1002/mco2.70194 · Cited by 59
The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies
Wang, H., Tang, R., Ling, J., & Jia, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1494802 · Cited by 65
Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer
Kasi, P. M., Afable, M. G., Herting, C. J., Lukanowski, M., & Jin, Z. (2023) · The Oncologist · doi:10.1093/oncolo/oyad262 · Cited by 47
Nobiletin in Cancer Therapy; Mechanisms and Therapy Perspectives
Moazamiyanfar, R., Rezaei, S., Aliashrafzadeh, H., Rastegar‐Pouyani, N., Jafarzadeh, E., Moloudi, K., Khodamoradi, E., Zhaleh, M., Taeb, S., & Najafi, M. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230426115424 · Cited by 41
Gao, Y., & Tian, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411811 · Cited by 43
“The PI3K/AKT/MTOR signaling pathway plays a key role in a variety of cancers, including CRC, such as cell proliferation, cell metastasis, and cell survival [166,167].”
BackgroundMao, Y.-T., Wang, J., Wang, Y., Fu, Z., Dong, L., & Liu, J. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01905-8 · Cited by 40
Chan, S., Wang, X., Wang, Z., Du, Y., Zuo, X., Chen, J., Sun, R., Zhang, Q. H., Li, L., Yang, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.82000 · Cited by 41
“Complex signaling pathways, including Wnt, Jak/Stat, PI3K/Akt, Mapk, TGF-β, NF-κB, and Notch, have a significant role in CRC pathogenesis [4-10].”
Therapeutic Potential of Chlorogenic Acid in Chemoresistance and Chemoprotection in Cancer Treatment
Cortez, N., Villegas, C., Burgos, V., Ortíz, L., Cabrera‐Pardo, J. R., & Paz, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105189 · Cited by 38
“…kinases) and PI3K/Akt/mTOR (phosphatidylinositol 3-kinase/protein kinase B/ rapamycin target in T cells) are important intracellular signaling pathways that regulate a variety of cellular processes, including survival, proliferation, differentiation, metastasis, and angiogenesis [100].”
BackgroundCTC-neutrophil interaction: A key driver and therapeutic target of cancer metastasis
Hu, C., Long, L., Lou, J., Leng, M., Yang, Q., Xu, X. M., & Zhou, X. W. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117474 · Cited by 40
Su, Y. J., Leng, M., Yang, Q., Jiang, W., Xiang, G., Long, L., & Zhou, X. W. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03522-8 · Cited by 38
“…facilitating tumor cell migration [66]; EGF, HGF, and PDGF activate the MAPK and PI3K/AKT pathways in CTCs, thereby promoting their growth [62, 67]; IL-1β stimulates CTCs proliferation [68]; and VEGF supports tumor metastasis by promoting angiogenesis and vascular permeability in…”
Kasprzak, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043665 · Cited by 44
“One of the pathways that plays an important role in the pathogenesis and progression of CRC is the insulin-like growth factor (IGF) system [3,4].”
BackgroundSabbah, D. A., Hajjo, R., Bardaweel, S. K., & Zhong, H. A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2338100 · Cited by 36
“Somatic mutations of PI3KCA have been identified in breast, lung, colorectal, kidney, glioblastoma, and gastric cancers [15,32–35].”
BackgroundExploring the Key Signaling Pathways and ncRNAs in Colorectal Cancer
Lee, Y. J., Kim, W. R., Park, E. G., Lee, D. H., Kim, J., Shin, H. J., Jeong, H.-S., Roh, H.-Y., & Kim, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084548 · Cited by 36
“These families are identified to play important roles in the development, progression, and oncogenic impact of CRC, acting individually or concurrently within the specific cellular context and signaling requirements in CRC [5,50].”
BackgroundMitogen signaling strength and duration can control cell cycle decisions
Nussinov, R., Zhang, W., Liu, Y., & Jang, H. (2024) · Science Advances · doi:10.1126/sciadv.adm9211 · Cited by 34
“Fourth, as to shared commonalities, both major mitogenic signaling pathways, MAPK and PI3K/mTOR, are frequently involved in cancer ( 40 , 106 – 108 ).”
Interactions of melatonin with various signaling pathways: implications for cancer therapy
Mihanfar, A., Yousefi, B., Azizzadeh, B., & Majidinia, M. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02825-2 · Cited by 35
“Exosomes released by gastric tumor cells and bone marrow mesenchymal stem cells contain wide spectrum of proteins and mediators that can in part, stimulate proliferation of the adjacent tumor cells via PI3K/ Akt/mTOR and ERK/MAPK and seem to be an important mechanism for intercellular communication [59].”
BackgroundZhai, Y., Sun, J., Sun, C., Zhao, H., Li, X., Yao, J., Su, J., Xu, X., Xu, X., Hu, J., et al. (2022) · Phytotherapy Research · doi:10.1002/ptr.7561 · Cited by 33
“…for the treatment of CRC. Signaling pathways such as PI3K/AKT/mTOR, Wnt/β-catenin, TGF-β/Smads, and Hedgehog pathways undergo aberrant changes during development of CRC. Abnormal activation of the PI3K/AKT/ mTOR pathway leads to unlimited CRC cell growth and drug resistance (Stefani et al., 2021).”
BackgroundMezher, M., Abdallah, S., Ashekyan, O., Shoukari, A. A., Choubassy, H., Kurdi, A., Temraz, S. N., & Nasr, R. (2023) · Cells · doi:10.3390/cells12071081 · Cited by 33
Obesity and Colorectal Cancer: A Narrative Review
Miranda, B. C. J., Tustumi, F., Nakamura, E. T., Shimanoe, V. H., Kikawa, D., & Waisberg, J. (2024) · Medicina · doi:10.3390/medicina60081218 · Cited by 37
“Moreover, IR is associated with dysregulation of other metabolic pathways, such as increased lipolysis and free fatty acid release, which can further contribute to cancer development through mechanisms involving inflammation, oxidative stress, and altered cell metabolism [43].”
BackgroundN7-methylguanosine modification in cancers: from mechanisms to therapeutic potential
Wu, Q., Fu, X., Liu, G., He, X., Li, Y., & Ou, C. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01665-7 · Cited by 33
Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers
Shan, K. S., Bonano-Rios, A. M., Theik, N. W. Y., Hussein, A. M., & Blaya, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041973 · Cited by 35
“…metastasis of colorectal cancer cells by affecting the metabolism and uptake of glucose and amino acids and participating in the cellular process [55]. mTOR signaling participates in vascular epidermal growth factor (VEGF)-mediated angiogenesis and AKT activates endothelial nitric oxide…”
BackgroundZhang, Z., Chen, X., Li, Y., Zhang, F., Quan, Z., Wang, Z., Yang, Y., Si, W., Xiong, Y., Ju, J., et al. (2024) · APOPTOSIS · doi:10.1007/s10495-024-01994-x · Cited by 33
Zheng, W., Guo, Y., Zhang, G., Bai, J., Song, Y., Song, X., Zhu, Q., Bao, X., Wu, G., & Zhang, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287133 · Cited by 31
“Intriguingly, via KEGG pathway enrichment analysis, the mTOR signaling pathway was found to be one of the most prominent enriched pathways (Fig 4C), which possesses a pivotal function in colorectal tumorigenesis [26].”
MethodLai, W., Xian, C., Chen, M., Luo, D., Zheng, J., Zhao, S., & Li, X. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110509 · Cited by 33
Hasan, G. M., Mohammad, T., Zaidi, S., Shamsi, A., & Hassan, M. I. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1696204 · Cited by 29
Kahkesh, S., Khoshnazar, S. M., Gholinezhad, Y., Esmailzadeh, S., Hosseini, S. A., Alimohammadi, M., & Mafi, A. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155316 · Cited by 29
Demir, K., Turgut, R., Şentürk, S., Işıklar, H., & Günalan, E. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4534 · Cited by 30
“These pathways are phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt), and mitogen-activated protein kinase (MAPK)/Ras (Stefani et al. 2021).”
Yu, Y., Yin, H., Wu, B., Zhao, W., Wang, Y., Aili, A., Yang, M., Yu, Q., & Yuan, X. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-024-01097-4 · Cited by 28
Insulin‑like growth factor in cancer: New perspectives (Review)
Wu, D., Dong, S., & Zhou, W. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13574 · Cited by 28
“The iGFs system is involved in the regulation of cancer progression through a variety of signaling pathways, including the MaPK signaling pathway (18), the Pi3K/aKT/mTor signaling pathway (19) and the nF‑ κ B signaling pathway (20).”
The remodeling roles of lipid metabolism in colorectal cancer cells and immune microenvironment
Zhong, J., GUO, J., ZHANG, X., FENG, S., Di, W., WANG, Y., & ZHU, H. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.027900 · Cited by 31
“Studies have shown that VEGF-A activates PI3K and phosphorylates PIP2 to PIP3 through binding with EGF receptor (EGFR), which is an important second messenger involved in AKT recruitment, activates mTOR, and finally causes cell growth and proliferation [66,67].”
BackgroundPostwala, H., Shah, Y., Parekh, P. S., & Chorawala, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02201-8 · Cited by 26
“By studying these pathways, researchers aim to unravel the complexities of CRC and develop more effective strategies for prevention, diagnosis, and treatment [110].”
BackgroundMolecular neuropathology of brain‐invasive meningiomas
von Spreckelsen, N., Kesseler, C., Brokinkel, B., Goldbrunner, R., Perry, A., & Mawrin, C. (2022) · Brain Pathology · doi:10.1111/bpa.13048 · Cited by 26
Wu, H., Wei, M., Li, Y., Ma, Q., & Zhang, H. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.910543 · Cited by 29
“Composition and Classification of Phosphatidylinositol-3-Kinase Serine/threonine and lipid kinases, including phosphomembrane-bound phosphatidylinositol-3 (PIP3) kinases, constitute the phosphatidylinositol-3-kinase (PI3K) family (Stefani et al., 2021; Yoshioka, 2021).”
BackgroundHasan, M. S. A., Emon, Y., Alshahrani, M. Y., Mizan, M., Uddin, M. B., Hasan, A. M. W., Sayeed, M. A., Mia, E., Yana, N. T., Hossan, R., et al. (2025) · Medical Oncology · doi:10.1007/s12032-025-02844-9 · Cited by 26
“In colorectal cancer (CRC), the PI3K/Akt/mTOR pathway is commonly altered and plays a key role in tumorigenesis and progression [32].”
Unraveling the complexities of colorectal cancer and its promising therapies – An updated review
Saha, S., Ghosh, S., Ghosh, S., Nandi, S., & Nayak, A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113325 · Cited by 30
Ulanja, M. B., Ntafam, C., Beutler, B. D., Antwi‐Amoabeng, D., Rahman, G. A., Ulanja, R. N., Mabrouk, T., Governor, S., Djankpa, F. T., & Alese, O. B. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.27096 · Cited by 24
“Overweight and obese individuals face a markedly increased risk of CRC as compared to the general population; over 10% of cases of CRC have been linked to overweight and obesity.(22,23) In light of the increasing incidence of RsCC relative to LsCC, we aimed to investigate the influence of overweight and obesity on CRC…”
BackgroundWang, Y. (2024) · Phytotherapy Research · doi:10.1002/ptr.8215 · Cited by 24
“Tumor suppressor genes like p53 may lose effectiveness due to mutation or loss in cancers (Stefani et al., 2021).”
Wang, S., Cheng, L., Wu, H., & Li, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.949656 · Cited by 26
“The PI3K/AKT/ mTOR signaling pathway is one of the most critical abnormal regulatory pathways in CRC, and the activation of this pathway is associated with cell proliferation and transformation, tumorigenesis, progression, angiogenesis, and drug resistance (75, 76) (Figure 3).”
BackgroundA Concise Review of the Role of the NKG2D Receptor and Its Ligands in Cancer
Boneva, E., Shivarov, V. S., & Ivanova, M. (2025) · Immuno · doi:10.3390/immuno5010009 · Cited by 24
“In contrast, growth factors present in the tumor microenvironment (TME) (EGFR, VEGF, IGF-1R) [101] activate the PI3K/AKT and RAS/RAF pathways, which enhance both NKG2DL mRNA translation and mTORC1 activity [102].”
Geng, Y., Geng, Y., Liu, X., Chai, Q., Li, X., Ren, T., & Shang, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1167930 · Cited by 23
Li, R., Wu, Y., Li, Y., Wen, S., Wang, A., Zhu, Y., Hu, X., Xia, Y., Ouyang, L., & Wang, G. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116040 · Cited by 28
Metabolic risk factors of colorectal cancer: Umbrella review
Molla, M. D., Symonds, E. L., Winter, J. M., Debie, A., & Wassie, M. M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104502 · Cited by 24
Wang, C., Peng, Y., Yang, H., Jiang, Y., Khalid, A. K., Zhang, K., Xie, S., Bermudez, L. E., Yang, Y., Zhang, L., et al. (2025) · eLife · doi:10.7554/elife.107132.3 · Cited by 22
Classical Angiogenic Signaling Pathways and Novel Anti-Angiogenic Strategies for Colorectal Cancer
Cao, M., Wang, Y., Lu, G., Qi, H., Li, P., Dai, X., & Lü, J. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100305 · Cited by 23
Madej, M., Gola, J. M., & Chrobak, E. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122768 · Cited by 25
“…kinase is capable of phosphorylating multiple factors in both the cytoplasm and cell nucleus, indirectly leading to changes in gene expression [35,53]. form, the protein kinase is capable of phosphorylating multiple factors in both the cytoplasm and cell nucleus, indirectly leading to changes in…”
Yasudome, R., Seki, N., Asai, S., Goto, Y., Kita, Y., Hozaka, Y., Wada, M., Tanabe, K., Idichi, T., Mori, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911616 · Cited by 25
Shakhpazyan, N. K., Михалева, Л. М., Bedzhanyan, A. L., Владиславовна, Г. З., Sadykhov, N. K., Mikhalev, A., Atiakshin, D., Buchwalow, I., Tiemann, M., & Orekhov, A. N. (2023) · Biomedicines · doi:10.3390/biomedicines11092361 · Cited by 23
Wu, Y., Luo, J., & Xu, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015222 · Cited by 22
“Despite the fact that the PI3K–AKT signaling pathway governs various cellular processes such as differentiation, metabolism, survival, and apoptosis, its abnormal activation contributes to the development of colorectal cancer malignancy [18].”
BackgroundDiscoidin Domain Receptor 1 Expression in Colon Cancer: Roles and Prognosis Impact
Arfi, K. B., Schneider, C., Bennasroune, A., Bouland, N., Wolak‐Thierry, A., Collin, G., Le, C., Toussaint, K., Hachet, C., Lehrter, V., et al. (2022) · Cancers · doi:10.3390/cancers14040928 · Cited by 21
Li, Z., Deng, L., Cheng, M., Ye, X., Yang, N., Fan, Z., & Sun, L. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5730 · Cited by 22
“The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signaling pathways, which are typically downstream of receptor tyrosine kinases, are implicated in BA‑induced CRC invasion (54,55).”
Weighty matters: Unraveling the impact of obesity on colorectal cancer and nutritional interventions
Simancas‐Racines, D., Reytor-González, C., Frías-Toral, E., Katsanos, C. S., & Hidalgo, R. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.004 · Cited by 21
Targeting the CXCR4/CXCL12 Axis to Overcome Drug Resistance in Triple-Negative Breast Cancer
Singh, D. D., Yadav, D. K., & Shin, D. (2025) · Cells · doi:10.3390/cells14181482 · Cited by 20
Rashid, A. A. A., Ashari, L. S., Shafiee, N. H., Ali, R. A. R., Lee, Y. Y., Shahril, M. R., & Mohamed, H. J. J. (2023) · BMC Public Health · doi:10.1186/s12889-023-16283-6 · Cited by 20
“In addition, raised plasma insulin levels and insulin-like growth factor-1, both known to promote tumor growth [27, 63].”
BackgroundEdo, G. I., Ndudi, W., Makia, R. S., Jikah, A. N., Yousif, E., Gaaz, T. S., Akpoghelie, P. O., Opiti, R. A., Isoje, E. F., Igbuku, U. A., et al. (2024) · Phytochemistry Reviews · doi:10.1007/s11101-024-10034-0 · Cited by 21
“These effects are carried out through multiple pathways, including Nuclear Factor Kappa B/ Mitogen-Activated Protein kinases (NF-B/ MAPK) and phosphatidylinositol 3-kinase /protein kinase B/mammalian target of rapamycin (PI3K/AKT/ mTOR) (Stefani et al. 2021).”
Zeid, M. M., El‐Badry, O. M., Elmeligie, S. E., & Hassan, R. A. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128346900241111115125 · Cited by 21
Huang, Z., & Jin, G. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00991 · Cited by 20
Feng, L., Si, J., Yue, J., Zhao, M., Qi, W., Zhu, S., Mo, J., Wang, L., Lan, G., & Liang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076413 · Cited by 32
“The TGF-beta, cGMP-PKG, cAMP, and VEGF signaling pathways [50] were identified as important for skeletal muscle development in pigs after birth.”
BackgroundXie, Q., Chu, Y., Yuan, W., Li, Y., Li, K., Wu, X., Liu, X., Xu, R., Cui, S., & Qu, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.04.001 · Cited by 20
“Acta Pharmaceutica Sinica B 2023;13(7):2963e2975”
Mu, B.-X., Li, Y., Ye, N., Liu, S., Zou, X., Qian, J., Wu, C., Zhuang, Y., Chen, M., & Zhou, J. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117342 · Cited by 19
Xie, J., Li, D., Niu, S., Sheng, Y., Shen, R., He, Y., Xu, C., Zhang, Y., Wang, T., & Xue, Y. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401009 · Cited by 19
Toledo, C. R., Tantawy, A. A., Fuscaldi, L. L., Malavolta, L., & Ferreira, C. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158553 · Cited by 19
“The PI3K/AKT/mTOR pathway regulates cell growth, proliferation, and survival [13,14], while the MAPK pathway controls gene expression and cell cycle progression [11,15].”
BackgroundLaurindo, L. F., Pomini, K. T., de Lima, E. P., Laurindo, L. F., Rodrigues, V. D., Oliveira, J. D. S. C., Araújo, A. C., Guiguer, É. L., Rici, R. E. G., Maria, D. A., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123280 · Cited by 21
Aslam, R., Richards, C. E., Fay, J., Hudson, L., Workman, J. A., Lee, C. L., Murphy, A. G., O’Neill, B. P., Toomey, S., & Hennessy, B. T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413264 · Cited by 19
“The MAPK and PI3K pathways are among the most frequently activated signalling pathways in human cancers, including CRC, and are closely interconnected [11,12].”
Zhang, Y., Xu, X., Yang, K., Wang, S., Zhang, T., Hui, F., Zheng, F., Geng, H., Xu, C., Xun, F., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176952 · Cited by 18
Stem Cell-Derived Extracellular Vesicles in Skin Antiaging Treatments
Park, J. Y., Jung, S. Y., Yoo, D., Lee, S., Go, D., Bui, V. D., Jung, W., You, D. G., Park, J. H., & Um, W. (2025) · ACS Nano · doi:10.1021/acsnano.4c17406 · Cited by 18
Yamada, K., Shioya, R., Nishino, K., Furihata, H., Hijikata, A., Kaneko, M. K., Kato, Y., Shirai, T., Kosako, H., & Sawasaki, T. (2023) · Nature Communications · doi:10.1038/s41467-023-43931-7 · Cited by 18
Zhang, Y., Chen, Y., Guo, Q., Zhang, Y., & Liu, A. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110072 · Cited by 18
Tang, X., Min, H., Ren, Y., Ji, M., Yan, X., Zeng, W., Lv, Y., Li, Y., & He, Y. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119008 · Cited by 20
The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy
Tufail, M., Gong, K., Ijaz, B., Patel, H. H., Lui, W., Wang, X., & Li, J. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101355 · Cited by 20
Implication of mTOR Signaling in NSCLC: Mechanisms and Therapeutic Perspectives
Gargalionis, A. N., Papavassiliou, K. A., & Papavassiliou, A. G. (2023) · Cells · doi:10.3390/cells12152014 · Cited by 16
Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
Yuan, T., Wu, R., Wang, W., Liu, Y., Kong, W., Yang, B., He, Q., & Zhu, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1136114 · Cited by 17
“To further demonstrate this conclusion, epidermal growth factor (EGF), a classical stimulator of MAPK signaling, was introduced in our study and we found that EGF stimulation significantly upregulated MAPK signaling (Figures 3A–C), which was consistent with previous studies (Stefani et al., 2021).”
ResultWang, J., Yang, K., Yang, X., Jin, T., Tian, Y., Dai, C., & Xu, F. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23723 · Cited by 15
Maparu, K., Chatterjee, D., Kaur, R., Kalia, N., Kuwar, O. K., Attri, M., & Singh, S. (2025) · Medical Oncology · doi:10.1007/s12032-025-02685-6 · Cited by 16
“ALK activation is frequently due to point mutations that enhance the enzymatic activity of ALK overexpression, and activation of ALK signaling leads to the phosphorylation of downstream proteins such as PI3K/ AKT, MAPKinase/ERK, and JAKinase/STAT pathways [88, 89].”
NUCKS1 promotes the progression of colorectal cancer via activating PI3K/AKT/mTOR signaling pathway
Liao-Liao, Z. H. U., Jing-Jie, S. H. I., Yong-Dong, G. U. O., Yang, C., Rong-Lin, W. A. N. G., Shan-Shan, L. I., Gan, D., Pei-Xiang, M. A., Jun-Qiang, L. I., & Hai-Chuan, S. U. (2023) · Neoplasma · doi:10.4149/neo_2023_221107n1088 · Cited by 14
“1038/nrc2254 [53] STEFANI C, MIRICESCU D, STANESCU-SPINU II, NICA RI, GREABU M et al.”
BackgroundHong, W., Xiong, Z., Wang, X., Liao, X., Liu, M., Jiang, Z., Min, D., Li, J., Guo, G., & Fu, Z. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01260-9 · Cited by 14
“The binding of EGF to EGFR can activate the PI3K/AKT/mTOR signalling pathway [19, 20].”
BackgroundSun, R., Tu, X., Chan, S., Wang, X., Ji, Y., Wang, Z., Yu, Z., Zuo, X., Zhang, Q. H., Chen, J., et al. (2024) · Journal of Cancer · doi:10.7150/jca.92633 · Cited by 14
“[ 11,12] It consists of three classical branches: ERK, JNK, and p38 MAPK.”
BackgroundZhu, W., Wu, C., Liu, Z., Zhao, S., Cheng, X., & Huang, J. C. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03383-5 · Cited by 14
Luo, C., Luo, J., Zhang, Y., Lu, B., Li, N., Zhou, Y., Chen, S., Wu, S., Zhang, Q., Dai, M., et al. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.04.006 · Cited by 19
“Hyperglycemia and insulin resistance lead to increased levels of insulin and IGFs, which can bind to their respective receptors and activate the PI3K/Akt and MAPK signaling cascades, 37 , 38 thereby stimulating cellular proliferation, survival, motility, angiogenesis, and suppressing apoptosis.”
Fatemi, N., Mirbahari, S. N., Tierling, S., Sanjabi, F., Shahrivari, S., AmeliMojarad, M., AmeliMojarad, M., Rezaei, M. M., Nobaveh, P., Totonchi, M., et al. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08774-2 · Cited by 15
Liu, L., Wuyun, T., Sun, X., Zhang, Y., Cha, G., & Zhao, L. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07685-y · Cited by 14
“The abnormal activation of the PI3K/Akt/mTOR signaling pathway has been extensively studied in various cancers, particularly in NSCLC [15 – 17].”
Metadata
- Authors
- Stefani, C., Miricescu, D., Stanescu-Spinu, I.-I., Nica, R. I., Greabu, M., Totan, A. R., & Jinga, M.
- Affiliations
- Department of Family Medicine and Clinical Base, ‘‘Dr. Carol Davila’ Central Military Emergency University Hospital, 051075 Bucharest, Romania
- Carol Davila University of Medicine and Pharmacy (RO)
- Department of Biochemistry, Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Blvd, 050474 Bucharest, Romania
- Spitalul Universitar de Urgenţă Militar Central Dr. Carol Davila (RO)
- Corresponding author
- Miricescu, Daniela
- Greabu, Maria
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-09-23
- Volume
- 22
- Issue
- 19
- Pages
- 10260
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8508474
- OpenAlex
- W3200117713
- Cited by
- 402
- References
- 206
- Citations by year
- 2026: 69 · 2025: 134 · 2024: 103 · 2023: 68 · 2022: 26 · 2021: 2
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- colorectal cancer, growth factors, PI3K/AKT/mTOR pathway, MAPK signaling, tumor microenvironment, EGFR, IGF-1 receptor, VEGF-A, growth factor inhibitors, colorectal cancer risk factors, colorectal cancer pathogenesis, cell proliferation and invasion
- MeSH terms
- Animals, Humans, Colorectal Neoplasms, Signal Transduction, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinases, Intercellular Signaling Peptides and Proteins, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

